Clearside Biomedical Inc Clsd Reports Q2 Loss Lags Revenue Estimates

```html

Clearside Biomedical Reports Quarterly Loss of 010 Per Share

Company Exceeds Zacks Consensus Estimate for Revenue

Earnings Surprise: 0%

Clearside Biomedical Inc. (CLSD) recently announced a quarterly loss of $0.10 per share, meeting the Zacks Consensus Estimate. Despite the loss, CLSD exceeded revenue expectations by 48.80% for the quarter ended June 2022, with revenues reaching $5.41 million.

```